ArticleClinical & experimental metastasis2025
Dosimetric comparison of fractionated gamma knife icon and cyber knife radiosurgery treatment plans in patients with intracranial metastatic tumors.
Article in Clinical & experimental metastasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to compare the dosimetric performance of GammaKnife ICON and CyberKnife S7 radiosurgery systems in the treatment of single brain metastases using a fractionated stereotactic schedule. Fifteen patients with single brain metastases were retrospectively and consecutively included. For each patient, treatment plans were generated using both GammaKnife ICON and CyberKnife S7 systems, delivering a total dose of 27 Gy in three fractions. Dosimetric parameters including Paddick Conformity Index (PCI), Gradient Index (GI), Heterogeneity Index (HI), beam-on time (BOT), and doses to organs at risk (OARs) were compared across modalities and stratified by target volume. GammaKnife plans showed significantly higher PCI (0.862 vs. 0.825; p < 0.05) and lower HI (1.94 vs. 2.09; p < 0.05), indicating superior dose conformity and acceptable heterogeneity. GI was lower for GammaKnife, though not statistically significant. BOT was significantly shorter for GammaKnife (14.2 vs. 34.3 min; p < 0.05). Brainstem doses were significantly lower in GammaKnife plans, especially for lesions close to critical structures. Volume-based subgroup analysis confirmed that GammaKnife consistently delivered more conformal and steep dose distributions across all tumor sizes. GammaKnife ICON demonstrates dosimetric superiority in conformity, gradient sharpness, and treatment efficiency. These advantages may translate into improved clinical outcomes, such as enhanced local control, reduced toxicity, and increased patient comfort through shorter treatment sessions and better motion management. Gamma Knife, CyberKnife, Brain Metastasis, Radiosurgery.
Indexed as
Identifiers
41065932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.